cDCBLD2 mediates sorafenib resistance in hepatocellular carcinoma by sponging miR-345-5p binding to the TOP2A coding sequence

Sorafenib is a first-line chemotherapy drug for treating advanced hepatocellular carcinoma (HCC). However, its therapeutic effect has been seriously affected by the emergence of sorafenib resistance in HCC patients. The underlying mechanism of sorafenib resistance is unclear. Here, we report a circu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruan, YeLing, Chen, TianYi, Zheng, LongBo, Cai, JingWei, Zhao, Hu, Wang, YaLi, Tao, LiYe, Xu, JunJie, Ji, Lin, Cai, XiuJun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535695/
https://www.ncbi.nlm.nih.gov/pubmed/37781045
http://dx.doi.org/10.7150/ijbs.86227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535695/
https://www.ncbi.nlm.nih.gov/pubmed/37781045
http://dx.doi.org/10.7150/ijbs.86227

Ejemplares similares